Ultrasound Gene Therapy Gets a $125M Shot

SonoThera closed a $125M Series B on June 10, 2026, to advance ultrasound-mediated genetic medicines into clinical trials.

29 Jun 2026

SonoThera pulled in $125 million on June 10, 2026, in an oversubscribed Series B backed by Vida Ventures and ARK Invest. The raise will push lead programs for Duchenne muscular dystrophy and autosomal dominant polycystic kidney disease into clinical trials, two conditions that have gone largely untreated by genetic medicine for decades. Investor appetite this strong signals something beyond routine biotech enthusiasm.

At the center of the company's pitch is a dual-technology platform built around precision delivery. RIPPLE, its proprietary ultrasound-mediated system, pairs with PORE payload engineering to reach multiple tissue types with both large DNA and RNA payloads, a technical hurdle that has tripped up conventional viral delivery for years. Clearing it matters because the therapeutic applications that become possible on the other side are considerably broader.

Viral vectors have long carried real baggage: safety concerns, manufacturing headaches, and hard dosing ceilings that have slowed uptake across the field. Ultrasound-mediated delivery avoids many of those problems entirely, and that practical advantage is a core part of what CEO Kenneth Greenberg says draws Big Pharma interest. The ability to redose patients over time, rather than committing to a single irreversible intervention, could fundamentally change how physicians manage chronic genetic diseases.

For the patients waiting on these programs, that flexibility is no small thing. Two flagship programs are now advancing toward clinical proof of concept, with a platform designed to scale across tissue types as those results come in. SonoThera isn't the only player chasing next-generation gene therapy, but few are moving with this combination of technical clarity and funding behind them.